Home
overview

R&D prices are skyrocketing ever higher, whilst the drug development industry feels the squeeze of the recession. With this ever-increasing need to ensure a cost-effective and efficient portfolio, the planning and preparation for each drug portfolio must be optimised to provide the maximum revenue for the minimum expenditure.

Expert speakers will explore and debate the key success factors for portfolio planning and lifecycle management, including risk assessment, effective decision making, market exclusivity and innovation of products in pharma.

This is the 8th conference in this winning annual series and we are certain it will be the best yet! With 20 expert speakers, 17 in-depth presentations and two interactive half-day workshops this will be the one conference in 2013 to attend for the very latest intelligence to help you develop winning strategies in an increasingly challenging marketplace.

  • Discover current and cutting-edge methods of portfolio management
  • Determine how to increase efficiency of a drug lifecycle in order to create a drug with minimum cost and maximum revenue
  • Explore drug pricing and profit: how to read the market to benchmark the appropriate cost of a drug
  • Learn about the emerging markets in the industry and how this leads to new drug discoveries, as well as which sectors are becoming increasingly important in drug research and discovery
  • Debate lifecycle management techniques and best practices for drug development, including prioritisation, optimisation and management of a drug development portfolio
  • Examine the best analysis techniques, which programs to use, and which methods will gain the most accurate and useful results

 

You should attend this event if you are a Senior Executive in the pharmaceutical industry with responsibilities in the following areas:

Product Lifecycle Management

Research and Development

Portfolio Management

Business Development

Strategic Planning

Licensing

Mergers and Acquisitions

Brand Management

Clinical Research

Patent Law

Regulatory affairs

Drug Development

Sales and Marketing

 

 

Last year's delegates included representatives from:

Aero Win Technology Corp; Defense Equipment & Support Organisation; Dorset County Council; Ealing Commissioning Consortium; Elster Group; Greater Madison CVB; Hewlett-Packard; IBP Conex Ltd.; In a Box Innovations; LIRNEasia; Ministry Of Information And Communication; Ministry Of Information And Communications; Qalhat Lng; Rexel Senate; Shenzhen Techrise Electronics Co Ltd; Socabank and Soval

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Tony Ellery

Tony Ellery, CEO, Ellery Pharma Consulting

9:10 Chain strategy for portfolio management/LCM

Richard Fazackerley

Richard Fazackerley, Director - Global Demand Chain Technology , Eisai

  • Designing products for a cost effective & efficient launch
  • Lifecycle management of the supply chain
  • Considerations for establishing a robust, reliable & flexible global supply chain
  • Product design to facilitate market access & LCM
  • 9:50 Concept of safety medicine

    Lucette  Doessegger

    Lucette Doessegger, Safety Risk Management/Global Head of Licensing and Early Development, F. Hoffmann La-Roche AG

  • Concept of Translational Safety Medicine
  • Approaches to integrated safety sciences
  • Implications of pre-clinical findings to human and pitfalls
  • 10:30 Morning Coffee

    11:00 Predictive analytic modelling different stages of drug development

    Vladimir Anisimov

    Vladimir Anisimov, Honorary Professor in the School of Mathematics and Statistics, University Of Glasgow

  • Main uncertainties and risks in design of late stage clinical trials
  • Analytic data-driven technique for predictive patient recruitment modelling
  • Predicting trial performance and site productivity
  • Analysis of randomization schemes and impact on statistical design and supply chain process
  • Risk-based analytic supply chain modelling
  • Quantitative analysis of different stages of drug development
  •  

    11:40 Portfolio management for early stage assets

    Florian  Jehle

    Florian Jehle, Principal, Catenion

  • Context for R&D Decision Making
  • Project Level decision making for Early Stage Assets
  • Portfolio level decision making
     
  • 12:20 Networking Lunch

    13:30 How and why product potential is underestimated

    John Ansell

    John Ansell, Director, John Ansell Consultancy

  • Examples of underestimation
  • Why underestimation rather than overestimation?
  • Planning to maximise commercial potential
  • 14:10 Enhancing readout from Phase I studies and MIST guidance

    Gerhard Gross

    Gerhard Gross, Director, Early Drug Developability, Janssen Research and Development

  • Regulatory environment for metabolites and safety of metabolites
  • Lundbeck's MIST strategy
  • Obtaining early information on human metabolites
  • Human metabolite exposure: New models in area
  • 14:50 Afternoon Tea

    15:20 The drug delivery contribution to life cycle management

    Howard Stevens

    Howard Stevens, Assistant Head of Institute and Professor of Drug Delivery, University of Strathclyde

  • New presentations of 'old' drugs vs 'new' drugs
  • Working with academics
  • The marketing impact of imaging in-vivo performance
  • Emerging drug delivery opportunities
     

     

  • 16:00 Proving the value of innovation: Lifecycle begins in phase II

    Pankaj Oza

    Pankaj Oza, Principal consultant, IDEA Pharma UK

  • Designing path-to-market based on what customers want
  • Gateways, bridges, high road, low roads: indication sequencing
  • Indications are not destinations; portfolios half empty or half full
  • Where is the strategy in the strategy: what should portfolio strategy mean?

     

  • 16:40 Current and cutting edge methods for strategic portfolio management in pharmaceuticals

    Roger  Holdsworth

    Roger Holdsworth, European Business Development Lead, Kromite

  • Factors influencing decision making in the internal and external environment
  • Decisive data - what do we need to take account of?
  • Multiple Objective Decision Analysis - an effective method for multifactorial analysis
  • Application to portfolio optimisation
  • 17:20 Chairman's Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Howard Stevens

    Howard Stevens, Assistant Head of Institute and Professor of Drug Delivery, University of Strathclyde

    9:10 Managing portfolio risks

    Kimber Hardy

    Kimber Hardy, Head of Valuation and Analysis, Portfolio Management , Merck Serono International S.A.

  • Types of Portfolio Risk. Acceptable levels of Pipeline Risk
  • The "Flaw of Averages". Uses of Monte Carlo Simulation. Ranges
  • Commercial and Technical Risks. Correlated risks in portfolios
  • Presenting Portfolio Risks: Decision-Making and Risk Management
  • 9:50 Is there a role for innovation in Project/Programme Management?

    Tom Halliwell

    Tom Halliwell, Associate Director, Programme Management, Norgine Ltd

  • What is the point of Innovation?
  • Which areas need innovation?
  • How can innovation be focused?

     

  • 10:30 Morning Coffee

    11:00 The role of financial modeling in pharmaceutical portfolio management

    Joachim Greuel

    Joachim Greuel, Adjunct Professor of Finance & Healthcare Management, IE Business School

    11:40 Putting portfolio risks into perspective

    Tim Harris

    Tim Harris, Managing Director (former Senior Director at GSK), Turnstone Business Solutions Ltd.

  • The types of risks to your portfolio
  • Why do the risks matter?
  • The importance of context
  • Strategies to manage the risks

     

  • 12:20 Networking Lunch

    13:30 Patent enforcement in Europe - recent developments

    Christopher Maierhöfer

    Christopher Maierhöfer, Attorney-at-law, Bird & Bird LLP

  • The current landscape in Europe
  • Ways to a patent with unitary protection
  • Trends in pharmaceuticals

     

  • 14:10 Sustainability of brand lifecycle management

    Tony Ellery

    Tony Ellery, CEO, Ellery Pharma Consulting

  • Challenges facing LCM in 2013 and beyond
  • Sustainable and non-sustainable LCM strategies
  • Creating an Integrated LCM Plan
     
  • 14:50 Afternoon Tea

    15:20 Building an IP portfolio for making deals

    Harry  Kraft

    Harry Kraft, Senior Patent Attorney , Ablynx

  • Platform IP versus project IP
  • Who looks at biotech IP, when and why
  • Difference between biotech IP and big pharma IP
  • Combining patents and know-how into an integrated IP strategy
  • Building and maintaining an IP portfolio for making deals 
  • 16:00 Patenting drugs and challenging drug patents under the new U.S. patent law

    Bruce Sunstein

    Bruce Sunstein, Attorneys at Law, Sunstein Kann Murphy & Timbers LLP

  • Strategies for dealing with expanded scope of prior art in the U.S.
  • Inter partes review procedure
  • The new post grant review procedure
  • 16:40 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Kimber Hardy

    Kimber Hardy

    Head of Valuation and Analysis, Portfolio Management , Merck Serono International S.A.
    Lucette  Doessegger

    Lucette Doessegger

    Safety Risk Management/Global Head of Licensing and Early Development, F. Hoffmann La-Roche AG
    Richard Fazackerley

    Richard Fazackerley

    Director - Global Demand Chain Technology , Eisai
    Tom Halliwell

    Tom Halliwell

    Associate Director, Programme Management, Norgine Ltd

    Bruce Sunstein

    Attorneys at Law, Sunstein Kann Murphy & Timbers LLP
    Bruce Sunstein

    Christopher Maierhöfer

    Attorney-at-law, Bird & Bird LLP
    Christopher Maierhöfer

    Florian Jehle

    Principal, Catenion
    Florian  Jehle

    Gerhard Gross

    Director, Early Drug Developability, Janssen Research and Development
    Gerhard Gross

    Harry Kraft

    Senior Patent Attorney , Ablynx
    Harry  Kraft

    Howard Stevens

    Assistant Head of Institute and Professor of Drug Delivery, University of Strathclyde
    Howard Stevens

    Joachim Greuel

    Adjunct Professor of Finance & Healthcare Management, IE Business School
    Joachim Greuel

    John Ansell

    Director, John Ansell Consultancy
    John Ansell

    Kimber Hardy

    Head of Valuation and Analysis, Portfolio Management , Merck Serono International S.A.
    Kimber Hardy

    Lucette Doessegger

    Safety Risk Management/Global Head of Licensing and Early Development, F. Hoffmann La-Roche AG
    Lucette  Doessegger

    Pankaj Oza

    Principal consultant, IDEA Pharma UK
    Pankaj Oza

    Richard Fazackerley

    Director - Global Demand Chain Technology , Eisai
    Richard Fazackerley

    Roger Holdsworth

    European Business Development Lead, Kromite
    Roger  Holdsworth

    Tim Harris

    Managing Director (former Senior Director at GSK), Turnstone Business Solutions Ltd.
    Tim Harris

    Tom Halliwell

    Associate Director, Programme Management, Norgine Ltd
    Tom Halliwell

    Tony Ellery

    CEO, Ellery Pharma Consulting
    Tony Ellery

    Tony Ellery

    Former Global Head of Lifecycle Management in Portfolio Management, Novartis, Ellery Pharma Consulting
    Tony Ellery

    Vladimir Anisimov

    Honorary Professor in the School of Mathematics and Statistics, University Of Glasgow
    Vladimir Anisimov

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 2nd Floor South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, United Kingdom, Link to Map
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.